Thermo Fisher Scientific

CorEvitas is expected to boost Thermo Fisher's annual adjusted earnings per share by 3 cents next year

Thermo Fisher has been on an acquisition spree in recent years as it strives to become a one-stop shop for biopharma services.

It completed a $2.6 billion buyout of UK-based diagnostics firm Binding Site last year, and spent about $17.4 billion in 2021 to buy clinical research services provider PPD.

Shares of Massachusetts-based Thermo Fisher were down 1.3% at $514 in early trading.

Analytical Instruments segment provides an offering of instruments and the supporting consumables, software and services that are used for a range of applications.

Thermo Fisher to acquire data provider CorEvitas for about $913 million.